A Digital Intervention (ACT on Vaping App) for Vaping Cessation in Young Adult E-Cigarette Users
NCT ID: NCT06909500
Last Updated: 2025-12-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
1372 participants
INTERVENTIONAL
2026-03-01
2027-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Smartphone Application (ACT on Vaping) for Vaping Cessation in Young Adults
NCT05897242
Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors
NCT05994209
Goal2QuitVaping for Nicotine Vaping Cessation Among Adolescents
NCT04951193
Research and Innovation to Stop E-cigarette/Vaping in Young Adults
NCT04974580
Use of a Smartphone Mobile Application (App) to Enhance Smoking Cessation Treatment
NCT03519451
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ARM I: Participants use the ACT on Vaping app (Version A) and receive a text messaging program to motivate and support quitting. Participants also receive incentivized text message check-ins at 2 weeks, 2 months, and 4 months to assess their vaping status.
ARM II: Participants use the ACT on Vaping app (Version B) and receive incentivized text message check-ins at 2 weeks, 2 months, and 4 months to assess their vaping status.
After completion of study intervention, participants are followed up at 3 and 6 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm II (ACT on Vaping app (Version B) + incentivized texts)
Participants receive access to the ACT on Vaping app including health education content. Participants receive incentivized text message check-ins at 2 weeks, 2 months, and 4 months to assess changes in vaping on study.
Smartphone app
Receive access to the ACT on Vaping app
Text Message
Receive incentivized text messages to access vaping status
Survey Administration
Ancillary studies
Arm I (ACT on Vaping app (Version A) + incentivized texts + intervention texts)
Participants receive access to the ACT on Vaping app utilizing Acceptance and Commitment Therapy. Participants also receive text message intervention content, as well as incentivized text message check-ins at 2 weeks, 2 months, and 4 months to assess changes in vaping on study.
Smartphone app
Receive access to the ACT on Vaping app
Text Message
Receive incentivized text messages to access vaping status
Text Message
Receive intervention text messages
Survey Administration
Ancillary studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Smartphone app
Receive access to the ACT on Vaping app
Smartphone app
Receive access to the ACT on Vaping app
Text Message
Receive incentivized text messages to access vaping status
Text Message
Receive intervention text messages
Survey Administration
Ancillary studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age of majority (to provide informed consent) in current state/territory of residence
* Current weekly user of e-cigarette product(s) for the last 30 days
* Has a smartphone; either an Android (running version 12 or higher) or iPhone (running iOS version 17 or higher, iPhone 11 or more recent)
* Experience downloading and using one or more apps on their smartphone
* Have a mobile data plan and/or access to WiFi to support the use of the ACT on Vaping app
* Has access to text messaging
* Has an email address
* United States (US) resident, with a US mailing address
* Willing to complete all study procedures
* Comfortable reading and writing in English
Exclusion Criteria
* Member of the same household as another research participant
* Currently in prison
* Google voice number as sole phone number, due to its association with fraudulent study entry attempts
* Is ineligible per fraud prevention protocol
* Employees/family of investigator or study center
18 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Fred Hutchinson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jaimee Heffner, PhD
Role: PRINCIPAL_INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2025-01611
Identifier Type: REGISTRY
Identifier Source: secondary_id
RG1125194
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.